<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276484</url>
  </required_header>
  <id_info>
    <org_study_id>0653-090</org_study_id>
    <secondary_id>2005_105</secondary_id>
    <nct_id>NCT00276484</nct_id>
  </id_info>
  <brief_title>To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)</brief_title>
  <official_title>A Multicenter, Rand., Double-Blind, Titration Study to Evaluate &amp; Compare the Efficacy &amp; Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 Mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To Evaluate and Compare the Efficacy and Safety of Ezetimibe Plus Atorvastatin Versus
      Atorvastatin in Hypercholesterolemic Patients at High Risk for Coronary Heart Disease Not
      Adequately Controlled on Atorvastatin 40 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent Change in LDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percent Change in HDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in Non-HDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Total-Cholesterol</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in Total-C = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Triglycerides (TG)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in TG = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in Apo B = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in Apo A-I = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in TC:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in LDL-C:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in Apo B:Apo A-I Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in non-HDL-C:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 6 in C Reactive Protein (CRP)</measure>
    <time_frame>Baseline and 6 Weeks</time_frame>
    <description>Percent Change in CRP = [(week 6 value - baseline value)/baseline value]*100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Attained Target Low-Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 6</measure>
    <time_frame>6 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">579</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 40 mg + ezetimibe 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Atorvastatin 40 mg by mouth, once a day for 6 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with LDL-C &gt;70 mg/dL &amp; on a stable dose of atorvastatin 40 mg

        Exclusion Criteria:

          -  Pregnant or lactating women or intending to become pregnant

          -  Patient with sensitivity or intolerance to ezetimibe or atorvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <reference>
    <citation>Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008 Dec 1;102(11):1495-501. doi: 10.1016/j.amjcard.2008.09.076. Epub 2008 Oct 23.</citation>
    <PMID>19026303</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <results_first_submitted>February 6, 2009</results_first_submitted>
  <results_first_submitted_qc>March 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2009</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In: 4/6/2006; Last Patient Last Visit 2/26/2008
96 centers worldwide (US, Canada)
Eligible patients include those on a stable dose of atorvastatin 40 mg; or patients with adjusted LDLC
pre-screen ranges who were treated with other lipid modifying therapy, or were statin and/or ezetimibe naïve.</recruitment_details>
      <pre_assignment_details>Patients received and were blinded to atorvastatin 40 mg for a 4/5- week run-in period.
Patients needed an LDL-C ≥ 70 mg/dL and ≤ 160 mg/dL at Visit 2 (week -1). Eligible patients were randomized at Visit 3 (Week 0) to either atorvastatin 80 mg or addition of ezetimibe 10 mg to their 40 mg dose of atorvastatin for a 6-week treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin + Ezetemibe</title>
          <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin</title>
          <description>Atorvastatin 80 mg every day for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="279"/>
                <participants group_id="P2" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not take time off work</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin + Ezetemibe</title>
          <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin</title>
          <description>Atorvastatin 80 mg every day for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="288"/>
            <count group_id="B2" value="291"/>
            <count group_id="B3" value="579"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" lower_limit="31" upper_limit="80"/>
                    <measurement group_id="B2" value="62" lower_limit="34" upper_limit="79"/>
                    <measurement group_id="B3" value="61.3" lower_limit="31" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein A-I</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154.0" spread="25.5"/>
                    <measurement group_id="B2" value="154.6" spread="25.0"/>
                    <measurement group_id="B3" value="154.3" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.3" spread="19.0"/>
                    <measurement group_id="B2" value="102.0" spread="18.8"/>
                    <measurement group_id="B3" value="101.7" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B:Apolipoprotein A-I ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.2"/>
                    <measurement group_id="B2" value="0.7" spread="0.2"/>
                    <measurement group_id="B3" value="0.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C Reactive Protein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" spread="2.7"/>
                    <measurement group_id="B2" value="1.5" spread="3.0"/>
                    <measurement group_id="B3" value="1.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-Density Lipoprotein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="10.5"/>
                    <measurement group_id="B2" value="47.2" spread="10.6"/>
                    <measurement group_id="B3" value="47.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.8" spread="16.2"/>
                    <measurement group_id="B2" value="89.8" spread="16.2"/>
                    <measurement group_id="B3" value="89.4" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-Density Lipoprotein-C:High-Density Lipoprotein-C ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="0.6"/>
                    <measurement group_id="B2" value="2.0" spread="0.6"/>
                    <measurement group_id="B3" value="2.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.7" spread="20.8"/>
                    <measurement group_id="B2" value="118.1" spread="21.9"/>
                    <measurement group_id="B3" value="117.9" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein-C:High-Density Lipoprotein-C ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" spread="0.8"/>
                    <measurement group_id="B2" value="2.6" spread="0.8"/>
                    <measurement group_id="B3" value="2.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.2" spread="21.4"/>
                    <measurement group_id="B2" value="165.3" spread="22.8"/>
                    <measurement group_id="B3" value="165.2" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol:High-Density Lipoprotein-C ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="0.8"/>
                    <measurement group_id="B2" value="3.6" spread="0.8"/>
                    <measurement group_id="B3" value="3.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132.5" spread="72.1"/>
                    <measurement group_id="B2" value="134.0" spread="72.1"/>
                    <measurement group_id="B3" value="133.5" spread="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C</title>
        <description>Percent Change in LDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C</title>
          <description>Percent Change in LDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set (FAS): The FAS population includes all randomized patients who took at least 1 dose of study medication and had a baseline (BL) value and at least one post BL value. Post BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.4" lower_limit="-29.6" upper_limit="-25.1"/>
                    <measurement group_id="O2" value="-11.0" lower_limit="-13.2" upper_limit="-8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline LDL-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>-13.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Percent Change in HDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C)</title>
          <description>Percent Change in HDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.6" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.1" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.551</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline HDL-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)</title>
        <description>Percent Change in Non-HDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)</title>
          <description>Percent Change in Non-HDL-C = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" lower_limit="-25.3" upper_limit="-21.4"/>
                    <measurement group_id="O2" value="-9.0" lower_limit="-11.0" upper_limit="-7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline non-HDL-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>-11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Total-Cholesterol</title>
        <description>Percent Change in Total-C = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Total-Cholesterol</title>
          <description>Percent Change in Total-C = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" lower_limit="-18.3" upper_limit="-15.4"/>
                    <measurement group_id="O2" value="-6.9" lower_limit="-8.4" upper_limit="-5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline Total-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>-7.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Triglycerides (TG)</title>
        <description>Percent Change in TG = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Triglycerides (TG)</title>
          <description>Percent Change in TG = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" lower_limit="-16.3" upper_limit="-8.2"/>
                    <measurement group_id="O2" value="-5.9" lower_limit="-10.2" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Nonparametric ANCOVA</method>
            <method_desc>ANCOVA using ranks based on normal scores (Tukey method) with model terms for treatment and baseline triglycerides value.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.5</ci_lower_limit>
            <ci_upper_limit>-3.1</ci_upper_limit>
            <estimate_desc>The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon’s rank sum test statistic.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B)</title>
        <description>Percent Change in Apo B = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B)</title>
          <description>Percent Change in Apo B = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" lower_limit="-19.6" upper_limit="-16.0"/>
                    <measurement group_id="O2" value="-7.7" lower_limit="-9.5" upper_limit="-5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline Apo B value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>-7.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I)</title>
        <description>Percent Change in Apo A-I = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I)</title>
          <description>Percent Change in Apo A-I = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.5" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-2.3" upper_limit="-0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline Apo A-I value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio</title>
        <description>Percent Change in TC:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio</title>
          <description>Percent Change in TC:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" lower_limit="-176.6" upper_limit="-14.4"/>
                    <measurement group_id="O2" value="-5.6" lower_limit="-7.2" upper_limit="-4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline Total-C:HDL-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>-8.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio</title>
        <description>Percent Change in LDL-C:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio</title>
          <description>Percent Change in LDL-C:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.4" lower_limit="-28.8" upper_limit="-24.0"/>
                    <measurement group_id="O2" value="-9.9" lower_limit="-12.3" upper_limit="-7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline LDL-C:HDL-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.9</ci_lower_limit>
            <ci_upper_limit>-13.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio</title>
        <description>Percent Change in Apo B:Apo A-I Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio</title>
          <description>Percent Change in Apo B:Apo A-I Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" lower_limit="-18.9" upper_limit="-14.9"/>
                    <measurement group_id="O2" value="-5.9" lower_limit="-7.9" upper_limit="-3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline Apo B:Apo A-I value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>-8.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio</title>
        <description>Percent Change in non-HDL-C:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio</title>
          <description>Percent Change in non-HDL-C:HDL-C Ratio = [(week 6 ratio - baseline ratio)/baseline ratio]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" lower_limit="-24.5" upper_limit="-19.9"/>
                    <measurement group_id="O2" value="-7.6" lower_limit="-9.9" upper_limit="-5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms: treatment and baseline non-HDL-C:HDL-C value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>-1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>-11.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 6 in C Reactive Protein (CRP)</title>
        <description>Percent Change in CRP = [(week 6 value - baseline value)/baseline value]*100%</description>
        <time_frame>Baseline and 6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 6 in C Reactive Protein (CRP)</title>
          <description>Percent Change in CRP = [(week 6 value - baseline value)/baseline value]*100%</description>
          <population>Full Analysis Set</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" lower_limit="-25.0" upper_limit="-11.1"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-18.7" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>Longitudinal Data Analysis (LDA)</method>
            <method_desc>LDA method of Liang and Zeger with model terms: treatment, time, and the interaction of time by treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Data for analysis was transformed by the natural log and the difference in geometric mean % change from BL calculated based on the difference in the back-transformed least squares means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Attained Target Low-Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 6</title>
        <time_frame>6 Weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin + Ezetemibe</title>
            <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Atorvastatin 80 mg every day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Attained Target Low-Density Lipoprotein Cholesterol (LDL-C) &lt;70 mg/dL at Week 6</title>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model terms: treatment and baseline LDL-C value</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.45</ci_lower_limit>
            <ci_upper_limit>12.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin + Ezetemibe</title>
          <description>Atorvastatin 40 mg + Ezetemibe 10 mg every day for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin</title>
          <description>Atorvastatin 80 mg every day for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9"/>
                <counts group_id="E2" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63"/>
                <counts group_id="E2" subjects_affected="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Carotid pulse decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

